MIRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mirum Pharmaceuticals Inc. (MIRM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple price target upgrades, a bullish moving average trend, and positive catalysts from its pipeline and acquisitions. While the recent financial performance shows a decline in net income and EPS, the revenue growth and gross margin improvements indicate long-term potential. The options data reflects a bullish sentiment with a low Open Interest Put-Call Ratio of 0.22 and no significant bearish activity. The lack of recent congress trading data or political involvement does not detract from the overall positive outlook.
The stock's technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200. The RSI is neutral at 59.912, and the MACD is negative but contracting, suggesting potential for upward momentum. The stock is trading near its pivot point of 101.692, with resistance at 104.844 and support at 98.541.
Multiple analyst upgrades with price targets as high as $140, reflecting confidence in the company's pipeline and acquisitions.
Strong revenue growth of 47.17% YoY in Q3
Positive developments in the rare disease pipeline, including the acquisition of Bluejay Therapeutics and progress on volixibat and brelovitug.
Stock awards and incentives to attract and retain talent, supporting long-term growth.
Decline in net income (-120.41% YoY) and EPS (-116.67% YoY) in Q3
No significant insider or hedge fund trading trends, indicating a lack of strong institutional activity.
In Q3 2025, revenue increased by 47.17% YoY to $133.01M, and gross margin improved to 80.8%. However, net income dropped by -120.41% YoY to $2.91M, and EPS declined by -116.67% YoY to $0.05.
Analysts are overwhelmingly positive on MIRM, with multiple upgrades and price targets ranging from $88 to $140. The company's pipeline, acquisitions, and pivotal readouts in 2026 are key drivers of this optimism.
